title: Tumors derived from antigen presenting cells.
abstract: Vaccine strategies aimed at enhancing the processing of tumor antigens by activated 'professional' antigen presenting cells (APCs) can sometimes result in the generation of systemic T-cell mediated anti-tumor immune responses capable of eradicating a micrometastatic tumor burden. This observation raises the interesting question of why certain tumors such as B-cell lymphomas or myeloid leukemias--malignancies in lineages normally characterized by potent APC capacity--fail to be eliminated by host T-cell responses. Potentially unique aspects of the immune response to such hematopoietic cancers are discussed in the context of the current understanding of factors regulating T-cell activation and tolerance. These considerations may have relevance for the application of cancer immunotherapy to this class of diseases.
authors.affiliation: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
authors.forename: H I
authors.initials: HI
authors.lastname: Levitsky
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000473:pathology*; D006801:Humans; D009369:Neoplasms / Q000209:etiology* / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000209:etiology* / Q000276:immunology*